26.07.2019 • News • Michael Quirmbach • Corden Pharma • People

Michael Quirmbach Appointed as CEO and President of CordenPharma

CordenPharma has appointed Michael Quirmbach as its new CEO and president....
CordenPharma has appointed Michael Quirmbach as its new CEO and president. Source: CordenPharma

CordenPharma has appointed Michael Quirmbach as its new CEO and president, effective Aug. 1, 2019. He is going to succeed Riku Rautsola who will transition to the role of a senior advisor to the executive leadership team.

Quirmbach joined CordenPharma in October 2014 as chief business officer and has been a member of the executive leadership team. Prior to joining CordenPharma, he held several management positions at Siegfried, Dr. Reddy’s and Solvias. Quirmbach holds a degree in chemistry and a PhD from the Max Planck Research Group at the Institute for Organic Catalysis Research in Rostock, Germany, as well as an MBA from La Salle University in Philadelphia, USA.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Top-Feature

most read

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.